Physician Assistant Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Tyler Johnson

Physician Assistant, Medical Waconia, MN Physician Assistant

NPI 1003362914 CMS profile 10873126

500 Maple Street, Waconia, MN 55387

Open in the dashboard

General payments

$28,179

82 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tyler Johnson of Waconia, MN is reported in the CMS Open Payments database as having received $28,179 across 82 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,631 25
2024 General $15,442 51
2023 General $68 4
2022 General $37 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tyler Johnson
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Tyler Johnson were reported at $12,631. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Tyler Johnson Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $0 $156 $41–$563 $132
2022 $37 $185 $55–$649 $149
2023 $68 $199 $58–$717 $160
2024 $15,442 $206 $62–$740 $164
2025 $12,631 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Lilly USA, LLC $26,877 65 payments
  2. Janssen Biotech, Inc. $1,103 4 payments
  3. Regeneron Healthcare Solutions, Inc. $75 4 payments
  4. Galderma Laboratories, L.P. $34 2 payments
  5. Organon LLC $17 2 payments
  6. E.R. Squibb & Sons, L.L.C. $16 1 payment
  7. Verrica Pharmaceuticals Inc. $16 1 payment
  8. Genzyme Corporation $14 1 payment
  9. UCB, Inc. $14 1 payment
  10. Sun Pharmaceutical Industries Inc. $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $24,300 24 payments
  2. Travel and Lodging $1,708 13 payments
  3. Food and Beverage $1,108 44 payments
  4. Consulting Fee $1,063 1 payment
Products named General payments · program years 2022–2025
  1. EBGLYSS $25,843 59 payments
  2. TREMFYA $1,103 4 payments
  3. DUPIXENT Inflammation And Immunology $61 3 payments
  4. TALTZ $44 3 payments
  5. OLUMIANT $37 2 payments
  6. AKLIEF $34 2 payments
  7. SOTYKTU $16 1 payment
  8. YCANTH $16 1 payment
  9. DUPIXENT Immunology $14 1 payment
  10. DUPIXENT Immunology And Inflammation $14 1 payment
  11. Other $40 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

687

Median for Physician Assistant: 241

Drug cost

$383,721

Median for Physician Assistant: $4,110

Branded share of claims

13%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cosentyx Sensoready (2 Pens) Secukinumab Brand 20 $146,638
Dupixent Pen Dupilumab Brand 35 $138,312
Otezla Apremilast Brand 13 $75,845
Calcipotriene Generic 25 $5,848
Tacrolimus Generic 23 $2,378
Doxycycline Hyclate Generic 73 $1,909
Ketoconazole Generic 114 $1,679
Fluorouracil Generic 22 $1,559
Clobetasol Propionate Generic 43 $1,392
Metronidazole Generic 31 $1,378

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$41,146

Medicare's payments for the services billed

Medicare patients

427

Average age 74

Services billed

1,693

189 women, 238 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Arthritis 38%
Diabetes 21%
Ischemic heart disease 21%
Chronic kidney disease 19%
Atrial fibrillation 15%
Depression 15%
Heart failure 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $1,087
$1,087 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $37
$37 35 —
AKLIEF
  • Galderma Laboratories, L.P. $34
$34 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $16
$16 — —
YCANTH
  • VERRICA PHARMACEUTICALS INC. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

82 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record